Longevity, as an investment theme, refers to the extension of healthy human lifespan and to the businesses that stand to benefit from it. In its narrow sense it covers companies studying the biology of ageing and developing drugs and therapies that target its underlying processes, an area that overlaps with genomics. In a broader sense it takes in firms that serve older populations, from medical devices to care and retirement products.
The case made for the theme rests on demographics, since the share of people over 65 is rising in most large economies, and on advances in biological research. Funds built around it are a form of thematic investing. Ageing is not recognized by regulators as a disease to be treated, most candidate therapies are at an early stage, and clinical trials frequently fail. In insurance, the same word names a risk: people living longer than expected raise the cost of each annuity and pension.